These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 17676256)
1. Effect of raloxifene treatment on osteocyte apoptosis in postmenopausal women. van Essen HW; Holzmann PJ; Blankenstein MA; Lips P; Bravenboer N Calcif Tissue Int; 2007 Sep; 81(3):183-90. PubMed ID: 17676256 [TBL] [Abstract][Full Text] [Related]
2. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis. Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988 [TBL] [Abstract][Full Text] [Related]
3. Effect of risedronate on osteocyte viability and bone turnover in paired iliac bone biopsies from early postmenopausal women. Qiu S; Phipps RJ; Ebetino FH; Palnitkar S; Sudhaker Rao D Calcif Tissue Int; 2010 Nov; 87(5):392-7. PubMed ID: 20809096 [TBL] [Abstract][Full Text] [Related]
4. Reduced iliac cancellous osteocyte density in patients with osteoporotic vertebral fracture. Qiu S; Rao DS; Palnitkar S; Parfitt AM J Bone Miner Res; 2003 Sep; 18(9):1657-63. PubMed ID: 12968675 [TBL] [Abstract][Full Text] [Related]
5. The effect of raloxifene on cardiac autonomic regulation in osteoporotic women. Gol M; Baris N; Guneri S; Posaci C Am J Obstet Gynecol; 2006 May; 194(5):1249-54. PubMed ID: 16647907 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Stepan JJ; Alenfeld F; Boivin G; Feyen JH; Lakatos P Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819 [TBL] [Abstract][Full Text] [Related]
7. Quantitative regional associations between remodeling, modeling, and osteocyte apoptosis and density in rabbit tibial midshafts. Hedgecock NL; Hadi T; Chen AA; Curtiss SB; Martin RB; Hazelwood SJ Bone; 2007 Mar; 40(3):627-37. PubMed ID: 17157571 [TBL] [Abstract][Full Text] [Related]
8. Differences in osteocyte density and bone histomorphometry between men and women and between healthy and osteoporotic subjects. Mullender MG; Tan SD; Vico L; Alexandre C; Klein-Nulend J Calcif Tissue Int; 2005 Nov; 77(5):291-6. PubMed ID: 16307389 [TBL] [Abstract][Full Text] [Related]
9. Effect of raloxifene on the vaginal epithelium of postmenopausal women. Delmanto A; Nahas-Neto J; Nahas EA; de Oliveira ML; Fernandes CE; Traiman P Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):187-92. PubMed ID: 18400357 [TBL] [Abstract][Full Text] [Related]
10. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial. Schaefers M; Muysers C; Alexandersen P; Christiansen C Menopause; 2009; 16(3):559-65. PubMed ID: 19423999 [TBL] [Abstract][Full Text] [Related]
11. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)]. Rosa J; Vanuga P; Payer J; Svobodník A Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288 [TBL] [Abstract][Full Text] [Related]
12. Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis. Brennan O; Kennedy OD; Lee TC; Rackard SM; O'Brien FJ J Orthop Res; 2011 Mar; 29(3):419-24. PubMed ID: 20886644 [TBL] [Abstract][Full Text] [Related]
13. Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration. Scharla S; Oertel H; Helsberg K; Kessler F; Langer F; Nickelsen T Curr Med Res Opin; 2006 Dec; 22(12):2393-402. PubMed ID: 17257453 [TBL] [Abstract][Full Text] [Related]
14. The role of estrogen in the control of rat osteocyte apoptosis. Tomkinson A; Gevers EF; Wit JM; Reeve J; Noble BS J Bone Miner Res; 1998 Aug; 13(8):1243-50. PubMed ID: 9718192 [TBL] [Abstract][Full Text] [Related]
15. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083 [TBL] [Abstract][Full Text] [Related]
16. Raloxifene plus ossein-hydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: a randomized trial. Pelayo I; Haya J; De la Cruz JJ; Seco C; Bugella JI; Diaz JL; Bajo JM; Repolles M Menopause; 2008; 15(6):1132-8. PubMed ID: 18791486 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the sexual function and quality of life in raloxifene treated postmenopausal women. Biri A; Korucuoglu U; Ilhan MN; Ciftci B; Bozkurt N; Guner H Arch Gynecol Obstet; 2009 Apr; 279(4):505-9. PubMed ID: 18690468 [TBL] [Abstract][Full Text] [Related]
19. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Follet H; Li J; Phipps RJ; Hui S; Condon K; Burr DB Bone; 2007 Apr; 40(4):1172-7. PubMed ID: 17240209 [TBL] [Abstract][Full Text] [Related]
20. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Ensrud K; Genazzani AR; Geiger MJ; McNabb M; Dowsett SA; Cox DA; Barrett-Connor E Am J Cardiol; 2006 Feb; 97(4):520-7. PubMed ID: 16461049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]